Last reviewed · How we verify

NCT05719779: Ronco-Onco

Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer.

Recruiting now NA Last updated 15 August 2024
What this trial tests

NA trial testing Ronco-Onco and MAD in Oral Cancer in 35 participants. Currently enrolling.

Timeline
3 February 2023
Primary endpoint
30 December 2025
30 December 2025

Quick facts

Lead sponsorCentre hospitalier de l'Université de Montréal (CHUM)
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposesupportive care
Enrollment35
Start date3 February 2023
Primary completion30 December 2025
Estimated completion30 December 2025
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

Adults 18 to 65, any sex, with Oral Cancer or Pharynx Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the Tolerance and Benefits of Mandibular Advanced Device (MAD) for Snoring and Sleep Apnea in Patients with Oropharyngeal Cancer (OPC): Mixed Design Study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Oral Cancer

Currently open trials in the same condition.

Other Centre hospitalier de l'Université de Montréal (CHUM) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05719779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing